NASDAQ · SERVICES-MEDICAL LABORATORIES · MID CAP
Fulgent Genetics, Inc. FLGT
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$322.7M
▲ 13.8% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-5.4%
Net margin · FY25
-18.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 322.7M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 19 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-5.4%
Return on equity, FY2025
ROE
Operating margin-28.2%
Net margin-18.8%
Return on assets-5.0%
Each USD of equity lost 5 cents this year.
Returned to shareholders
USD 10.9M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 10.9M
Share of profit-18.0%
Consecutive raises—
USD 10.9M in buybacks went back to shareholders in a year without profit.
Growth
−5.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−19.5%
−5.2%
+42.2%
Returned to shareholders
−47.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+10.3%
Change, 10 years—
The share count grew 10% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.2B
total assets, end of FY2025
Total assetsUSD 1.2B
EquityUSD 1.1B
CashUSD 50.2M
Current ratio6.48×
Equity funds 92% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.3
0.3
0.3
0.6
1.0
0.4
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.2
0.2
0.7
0.3
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.0
−0.2
0.2
0.7
0.3
0.0
−0.0
−0.0
·
·
·
Income tax $B
−0.0
−0.0
0.0
0.0
0.2
0.1
0.0
0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.0
−0.2
0.1
0.5
0.2
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−5.4
−3.8
−14.0
11.8
58.7
65.7
−0.6
−10.6
−4.6
−17.9
−243.5
−254.3
Shares out B
0.03
0.03
0.03
0.03
0.03
0.03
0.02
0.02
0.02
0.02
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed